Skip to main content
Signal8
Ferrara Napoleone profile photo

Napoleone Ferrara

CIK: 0001744779

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Kalaris Therapeutics, Inc. logo
KLRS

Kalaris Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Kalaris Therapeutics, Inc. logo
    KLRS

    Kalaris Therapeutics, Inc.

    Jun 3, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    9K shares-
  • Kalaris Therapeutics, Inc. logo
    KLRS

    Kalaris Therapeutics, Inc.

    Apr 10, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    18K shares-
  • Kalaris Therapeutics, Inc. logo
    KLRS

    Kalaris Therapeutics, Inc.

    Mar 18, 2025
    Award(A)
    Direct
    504K shares-

1-3 of 3

About Ferrara Napoleone

Ferrara Napoleone (SEC CIK 0001744779) files insider reports with the SEC as Director of Kalaris Therapeutics, Inc. (KLRS).

Signal8 holds 4 ownership filings by Ferrara Napoleone (1 Form 3, 3 Form 4), filed between Mar 18, 2025 and Jun 4, 2026. Those filings report 3 transactions, from Mar 18, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ferrara Napoleone's filings is in BERKELEY HEIGHTS, NJ.

Recent filings by Ferrara Napoleone

  • Jun 3, 2026: Grant or award of KLRS derivative securities (Form 4, code A).
  • Apr 10, 2025: Grant or award of KLRS derivative securities (Form 4, code A).
  • Mar 18, 2025: Grant or award of KLRS shares (Form 4, code A).

Other insiders filing for Kalaris Therapeutics, Inc. (KLRS)

How to read Form 4 transaction codes